×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Why do Good Clinical Practice Inspectors Do Things Differently and How can Approaches be Both Harmonized and Optimized
Session Chair(s)
Mandy Kaur Budwal-Jagait, MSc
Head of GCP
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
This forum will discuss Good Clinical Practice (GCP) inspection methods, collaboration and training among regulators and their inspectors as they respond to the evolving clinical trial regulatory landscape such as the implementation of ICH E6 R3 and novel trial methodologies
Learning Objective : Examine the reasons why regulators may inspect clinical trials in different ways; Compare the various inspection approaches used by different regulators; Explain how regulators are harmonizing inspection approaches and collaborating to share information, resources, and training; Analyze how regulators are preparing to implement ICH E6 R3 and its implications for inspections and inspector training.
Speaker(s)
Why do GCP Inspectors Do Things Differently and How can Approaches be Both Harmonized and Optimized
Representative Invited
FDA, United States
Why do GCP Inspectors Do Things Differently and How can Approaches be Both Harmonized and Optimized
Representative Invited
Health Canada, Canada
Why do GCP Inspectors Do Things Differently and How can Approaches be Both Harmonized and Optimized
Representative Invited
European Medicines Agency, Netherlands
Why do GCP Inspectors Do Things Differently and How can Approaches be Both Harmonized and Optimized
Representative Invited
Pharmaceuticals and Medical Devices Agency, Japan
Have an account?